{"bill":{"bill_id":1313183,"change_hash":"8f1fefe4617ef245a87e231c87e860f5","session_id":1658,"session":{"session_id":1658,"state_id":52,"year_start":2019,"year_end":2020,"prefile":0,"sine_die":1,"prior":1,"special":0,"session_tag":"Regular Session","session_title":"2019-2020 Regular Session","session_name":"116th Congress"},"url":"https:\/\/legiscan.com\/US\/bill\/HB5632\/2019","state_link":"https:\/\/www.congress.gov\/bill\/116th-congress\/house-bill\/5632\/all-info","completed":0,"status":1,"status_date":"2020-01-16","progress":[{"date":"2020-01-16","event":1},{"date":"2020-01-16","event":9}],"state":"US","state_id":52,"bill_number":"HB5632","bill_type":"B","bill_type_id":"1","body":"H","body_id":114,"current_body":"H","current_body_id":114,"title":"FDA Accountability for Public Safety Act","description":"To establish procedures regarding the approval of opioid drugs by the Food and Drug Administration.","pending_committee_id":2302,"committee":{"committee_id":2302,"chamber":"H","chamber_id":114,"name":"Energy And Commerce"},"referrals":[{"date":"2020-01-16","committee_id":2302,"chamber":"H","chamber_id":114,"name":"Energy And Commerce"}],"history":[{"date":"2020-01-16","action":"Introduced in House","chamber":"H","chamber_id":114,"importance":0},{"date":"2020-01-16","action":"Referred to the House Committee on Energy and Commerce.","chamber":"H","chamber_id":114,"importance":1}],"sponsors":[{"people_id":20077,"person_hash":"ngoor9ky","party_id":"1","state_id":52,"party":"D","role_id":1,"role":"Rep","name":"Andy Kim","first_name":"Andy","middle_name":"","last_name":"Kim","suffix":"","nickname":"","district":"HD-NJ-3","ftm_eid":44044858,"votesmart_id":179640,"opensecrets_id":"N00041370","knowwho_pid":628795,"ballotpedia":"Andrew_Kim_(New_Jersey)","sponsor_type_id":1,"sponsor_order":1,"committee_sponsor":0,"committee_id":0,"state_federal":0}],"sasts":[{"type_id":1,"type":"Same As","sast_bill_number":"SB418","sast_bill_id":1196942}],"subjects":[{"subject_id":13304,"subject_name":"Health"},{"subject_id":13146,"subject_name":"Congressional oversight"},{"subject_id":13156,"subject_name":"Department of Health and Human Services"},{"subject_id":13593,"subject_name":"Drug safety, medical device, and laboratory regulation"},{"subject_id":13345,"subject_name":"Drug trafficking and controlled substances"},{"subject_id":13737,"subject_name":"Federal officials"},{"subject_id":13787,"subject_name":"Food and Drug Administration (FDA)"},{"subject_id":13199,"subject_name":"Government ethics and transparency, public corruption"},{"subject_id":13639,"subject_name":"Marketing and advertising"},{"subject_id":13490,"subject_name":"Prescription drugs"}],"texts":[{"doc_id":2104536,"date":"2020-01-19","type":"Introduced","type_id":1,"mime":"application\/pdf","mime_id":2,"url":"https:\/\/legiscan.com\/US\/text\/HB5632\/id\/2104536","state_link":"https:\/\/www.congress.gov\/116\/bills\/hr5632\/BILLS-116hr5632ih.pdf","text_size":322591,"text_hash":"db589fdca255d31bbd0f10e4b540d9e0"}],"votes":[],"amendments":[],"supplements":[],"calendar":[]}}